VetStem Biopharma specializes in regenerative veterinary medicine, utilizing a patented stem cell therapy derived from an animal's own adipose (fat) tissue. This innovative approach allows veterinarians to treat various conditions, particularly orthopedic injuries and arthritis in dogs, cats, and horses. The stem cells, known as VetStem Regenerative Cells (VSRC™), are processed to concentrate their regenerative properties and are injected into affected areas to alleviate pain and inflammation. The therapy has shown efficacy in treating conditions such as osteoarthritis, tendon and ligament injuries, and joint diseases, with a reported low adverse reaction rate across different animal species.

The science behind VetStem's technology is rooted in the multipotent nature of stem cells, which can differentiate into various tissue types, including bone, cartilage, and muscle. The stromal fraction harvested from adipose tissue contains a diverse mixture of regenerative cells, including mesenchymal stem cells (MSCs) and endothelial progenitor cells, which play crucial roles in tissue repair and regeneration. VetStem's regenerative cell therapy not only targets specific injuries but also promotes a broader healing response through mechanisms such as anti-inflammatory effects, trophic support, and enhanced angiogenesis. This comprehensive approach positions VetStem as a leader in the field of regenerative medicine for animals, with a growing body of evidence supporting its effectiveness in clinical applications.

United States

VetStemprovides veterinarians and owners with a way to treat dogs, horses and cats with the animal's own stem cells.

VetStem Biopharma

Company Details